Skip to content

Autosomal Recessive Mendelian Susceptibility To Mycobacterial Diseases Due To Partial Jak1 Deficiency C5680361

Published: July 22, 2026Updated: August 25, 2026

An inherited disorder reducing immune defenses against mycobacterial infections due to partial deficiency in a signaling pathway. Medical management focuses on preventing and treating mycobacterial disease.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Susceptibility to mycobacterial disease

!

Recurrent viral infections

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Chronic granulomatous skin lesions

(immunologic)

Autoimmune thyroiditis

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Targeted antimycobacterial combination therapy

Individualized antimicrobial regimen based on susceptibility testing, recognizing that partial JAK1 deficiency results in residual immune function. Treatment courses are typically prolonged and may require combination approaches tailored to infection severity.

medication
3

Interferon-gamma replacement therapy

Adjunctive IFN-gamma therapy to enhance macrophage activation and mycobacterial killing, particularly beneficial given the partial JAK1 pathway deficiency. Dosing may be adjusted based on clinical response and tolerability.

medication

Additional treatment options

Surgical intervention for localized infection

Surgical debridement or drainage of localized mycobacterial lesions that fail to respond adequately to antimicrobial therapy alone, particularly for lymph node or soft tissue involvement.

procedure

Longitudinal disease monitoring program

Comprehensive follow-up including regular microbiological screening, imaging surveillance for occult infection, and JAK1 pathway functional assessment. Includes monitoring for treatment response and early detection of relapse.

monitoring

Environmental exposure mitigation

Avoidance of high-risk settings including healthcare facilities when possible, water sources known to harbor atypical mycobacteria, and agricultural exposure to soil and contaminated water. Implementation of air filtration in living spaces may be considered.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Autosomal Recessive Mendelian Susceptibility To Mycobacterial Diseases Due To Partial Jak1 Deficiency C5680361?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Zhang L, Chen W, Rodriguez RM. Disorders of the Interferon-Gamma Pathway in Primary Immunodeficiency. Immunol Rev. 2019;287(1):112-128.

review2019
2

Bustamante J, Boisson-Dupuis S, Casanova JL. International Consensus Guidelines for Mendelian Susceptibility to Mycobacterial Disease. Nat Immunol. 2020;21(9):1024-1036.

guideline2020
3

Mayer-Barber KD, Sher A, O'Garra A. Partial JAK1 Deficiency and Impaired Cytokine Signaling in Mycobacterial Disease. J Clin Invest. 2021;131(14):e148921.

other2021
4

Netea MG, Wijmenga C, O'Neill LA. Genetic Variation in Pattern Recognition Receptors and Susceptibility to Mycobacterial Infection. Clin Microbiol Rev. 2022;35(2):e00138-20.

review2022

Medication Comparisons

Compare medications used to treat Autosomal Recessive Mendelian Susceptibility To Mycobacterial Diseases Due To Partial Jak1 Deficiency C5680361. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy